Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$72.83 USD
-1.07 (-1.45%)
Updated May 6, 2024 04:00 PM ET
After-Market: $73.01 +0.18 (0.25%) 6:44 PM ET
1-Strong Buy of 5 1
D Value D Growth D Momentum D VGM
Brokerage Reports
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 21 - 40 ( 714 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Increased Investment in QTORIN Should Drive Added Cash Flow
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for LGND 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
3Q23 Results; Continued Shopping, Streamlining and Royalty Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
New Royalty to Hit Immediately; Thesis Keeps Plugging Away; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Investments Across Different Need Spectrums; Ligand Buys 13% Interest in Soticlestat
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Ligand Acquires Novan Assets, Offering Future Financial Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Sparsentan Reinforced; PROTECT Study Shows Long-Term Kidney Function Preservation
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Success With Strategy and Streamlining; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J